About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
  > INVESTORS
  Overview
  Corporate Structure
  Corporate Governance
  Company History
  Annual General Meeting
  Postal Ballot
  Investor FAQs
  Stock Info
  Financial Results
  Subsidiary Financials
  Annual Report
  Disclosure to Stock Exchange
  Nomination form
  Press Releases
  Presentations
  Analyst Coverage
  Investor Contacts
  
  
  FY 2016 - 2017
  
  April 2017
  March 2017
  February 2017
  January 2017
  December 2016
  November 2016
  October 2016
  September 2016
  August 2016
  July 2016
  June 2016
  May 2016
  April 2016
     
 
Disclosure to Stock Exchange

  August 2017
17 Aug

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
16 Aug Company Statement on Status of EMA Dossiers Download Pdf
11 Aug Incorporation of WOS Download Pdf
07 Aug Intimation Regarding Analysts / Institutional Investors Meet Download Pdf
  July 2017
31 Jul Company Statement on USFDA Visit in May/June2017. CAPA is under Implementation Download Pdf
31 Jul Intimation Regarding Analysts / Institutional Investors Meet Download Pdf
14 Jul Press Release titled "FDA Oncologic Drugs Advisory Committee Unanimously Recommends Approval of Mylan and Bioconís Proposed Biosimilar Trastuzumab" Download Pdf
09 Jul Company's Statement on the outcome of pre-approval inspection audits by French health agency, L'Agence nationale de securite du medicament et des produits de sante (ANSM) on behalf of European Medicines Agency (EMA) Download Pdf
  June 2017
23 Jun Intimation Regarding Analysts / Institutional Investors Meet Download Pdf
20 Jun Intimation Regarding Analysts / Institutional Investors Meet Download Pdf
11 Jun Press Release titled "Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association's 77th Scientific Sessions" Download Pdf
1 Jun Intimation Regarding Analysts / Institutional Investors Meet Download Pdf
  May 2017
11 May Intimation Regarding Analysts / Institutional Investors Meet Download Pdf
10 May Biocon Statement in response to Media Reports on USFDA Form 483s for Biocon Limited. Download Pdf
08 May Newspaper Advertisement For Dispatch Of Postal Ballot Notice And Postal Ballot Form. Download Pdf
05 May Notice Of Postal Ballot Download Pdf
  April 2017
28 Apr Intimation regarding Analyst / Institutional Investor Meet Download Pdf
28 Apr Presentation - Analysts/Institutional Investors Meet Download Pdf
27 Apr  Outcome of Board Meeting Download Pdf
  March 2017
30 Mar  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
27 Mar  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
15 Mar  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
06 Mar  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
03 Mar  Biocon's statement in response to Delhi  High Court Interim Order Download Pdf
02 Mar  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
  February 2017
27 Feb  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
24 Feb  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
22 Feb  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
16 Feb  USFDA accepts Biologics License Application  (BLA) for Mylan and Biocon's proposed  Biosimilar Pegfilgrastim for Review Download Pdf
14 Feb  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
07 Feb  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
  January 2017
30 Jan  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
24 Jan  Biocon Q3 FY17 Net Profit Up 65% at Rs 171  Crore; Revenue Rises 32% at Rs 1092  Crore; EBITDA Increases 57% to Rs 324  Crore Download Pdf
11 Jan  U.S. FDA Accepts Biologics License  Application (BLA) for Mylan and Biocon's  Proposed Biosimilar Trastuzumab Download Pdf

  December 2016
27 Dec  Journal of the American Medical Association  (JAMA) Publishes Mylan and Biocon's  Proposed Biosimilar Trastuzumab Phase 3  Data Download Pdf
20 Dec  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
17 Dec  Transfer of shares to Investor Education  and Protection Fund Download Pdf
16 Dec  Disclosure under Regulation 30 of SEBI  (LODR) Regulations, 2015 - Change in Key  Managerial Personnel Download Pdf
13 Dec  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
13 Dec  Disclosure under Regulation 30 of SEBI  (LODR) Regulations, 2015 Download Pdf
06 Dec  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
  November 2016
29 Nov  Biocon's Novel Diabetes Education Initiative  for Medical Practitioners 'ABIDE' Awarded  by RSSDI Download Pdf
22 Nov  Intimation regarding Analysts / Institutional  Investors Meet Download Pdf
17 Nov  Intimation regarding Analysts / Institutional  Investors Meet Download Pdf
15 Nov  Intimation regarding Analysts / Institutional  Investors Meet Download Pdf
11 Nov  Intimation regarding Analysts / Institutional  Investors Meet Download Pdf
09 Nov  Intimation regarding Analysts / Institutional  Investors Meet Download Pdf
08 Nov  Mylan and Biocon Announce U.S. FDA  Submission for Proposed Biosimilar  Trastuzumab Download Pdf
03 Nov  Mylan and Biocon Announce Regulatory  Submission for Insulin Glargine Accepted  for Review by European Medicines Agency Download Pdf
  October 2016
24 Oct  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
20 Oct  Unaudited Financial Results for the quarter  and period ended Sep. 30, 2016
Download Pdf
  September 2016
29 Sep  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
23 Sep  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
19 Sep  Biocon Appoints Suresh Subramanian as  Head of Branded Formulations (India)  Business Download Pdf
14 Sep  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
07 Sep  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
01 Sep  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
  August 2016
26 Aug  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
25 Aug  Mylan and Biocon Announce Regulatory  Submission for Proposed Biosimilar  Trastuzumab Accepted for Review by  European Medicines Agency Download Pdf
24 Aug  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
17 Aug  Intimation regarding Analyst / Institutional  Investor meet Download Pdf
9 Aug  Intimation regarding Analyst / Institutional  Investor meet Download Pdf
2 Aug  Intimation regarding Analyst / Institutional  Investor meet Download Pdf
  July 2016
28 July  Biocon Initiates "Ek Prayaas" Nationwide  Awareness Program on Hepatitis C Download Pdf
21 July  Biocon Reports a Strong Q1FY17
 Revenues at Rs 952 Crore, up by 11 %;  EBITDA Up 15% to Rs 271 Crore
 Net Profit Up 17% at Rs 147 Crore
Download Pdf
21 July  Mylan & Biocon Announce Regulatory  Submission for Proposed Biosimilar  Pegfilgrastim Accepted for Review by  European Medicines Agency Download Pdf
15 July  Biocon's Insulin Glargine Launched in Japan Download Pdf
  June 2016
27 Jun  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
24 Jun  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
23 Jun  Biocon, Quark Announce Initiation of Pivotal  Phase II/III Study of QPI-1007 in Rare Eye  Disease in India Download Pdf
22 Jun  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
16 Jun  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
10 Jun  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
04 Jun  Mylan and Biocon to Present Phase 3  Trastuzumab Biosimilar Data at the  American Society of Clinical Oncology  (ASCO) Annual Meeting Download Pdf
03 Jun  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
01 Jun  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
  May 2016
30 May  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
26 May  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
26 May  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
18 May  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
12 May  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
5 May  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
3 May  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf

  April 2016
26 Apr  Biocon Q4FY16 Net Profit at Rs 361 Cr  Revenue Crosses Rs 1,000 Cr; Up 17% FY  16 Revenues up 14% at Rs 3,570 Cr  Net  Profit at Rs 896 CrDownload Pdf
26 Apr  Intimation Regarding Appointment of  Director Download Pdf




 
     
 March 2016
 February 2016
 January 2016
 December 2015
 
 
     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2016, Biocon. All Rights Reserved